Takeda Pharmaceutical Co Ltd (TSE:4502)
円 4205 103 (2.51%) Market Cap: 6.60 Til Enterprise Value: 10.97 Til PE Ratio: 46.05 PB Ratio: 0.90 GF Score: 76/100

Ovid Therapeutics Inc. - Special Call Transcript

Aug 25, 2020 / 12:00PM GMT
Release Date Price: 円4056 (+0.22%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Ovid Therapeutics Conference Call. (Operator Instructions) It is now my pleasure to turn the call over to Jeff Rona, Consulting CFO of Ovid Therapeutics. Please go ahead, sir.

Jeffrey Rona;Consulting CFO

Thank you, operator, and thank you, everyone, for dialing in today.

Earlier this morning, Ovid and Takeda announced positive top line results from the Phase II ELEKTRA trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome. The press release can be found on Ovid's website at www.ovidrx.com. Please note that we will have a webcast slide to accompany this call. For those dialing in, it may be helpful to go to the Investors page of the Ovid website and access the webcast player now if you haven't done so already. A PDF of the webcast slides will also be made available.

Joining me on the call this morning are Dr. Jeremy Levin, Chairman and Chief Executive Officer of Ovid; and Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot